Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
154 results about "Benzopyrone" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Benzopyrone may refer to either of two ketone derivatives of benzopyran which constitute the core skeleton of many flavonoid compounds: Chromone Coumarin Certain simple benzopyrones have clinical medical value as an edema modifiers. Coumarin and other benzopyrones, such as 5,6 benzopyrone, 1,2 benzopyrone, diosmin and others are known to stimulate macrophages to degrade extracellular albumin, allowing faster resorption of edematous fluids. Naturally occurring coumarin is also the basis for various 4-hydroxybenzopyrone-based molecules which occur naturally dicoumarol and are made synthetically warfarin and function as anticoagulants.
Mitochondria-targeted antioxidants
ActiveUS20080031862A1Protect mitochondrionHigh energyCosmetic preparationsBiocideDiseasePersonal care
The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and / or provide therapy to individuals at risk and / or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.
Owner:NATREON INC +1
Parp Modulators and Treatment of Cancer
The invention relates to a method of modulating poly(ADP-ribose)polymerase-1 (PARP-1) activity in a mammal comprising administering to a mammal an effective amount of an organic aromatic compound having from 4 to about 35 carbon atoms, wherein said organic aromatic compound is capable of binding the arginine-34 moiety located in Zinc finger-1 of the PARP-1 enzyme and wherein said organic aromatic compound has electron donating capabilities such that it's π-electron system will interact with the positively charged (cationic) guanidinium moiety of the specific arginine-34 residue of the Zinc-1 finger of PARP-1 and does not contain benzamide or lactam substituents. In particular, substituted benzopyrones and substituted indoles and their pharmaceutical compositions containing such compounds that modulate the activity of PARP-1, are described. The invention is also directed to the composition of matter, kits and methods for their therapeutic and / or prophylactic use in treating diseases and disorders described herein, by administering effective amounts of such compounds. Preferably, the compositions and methods provided herein inhibit PARP activity.
Owner:BIPAR SCI INC
Therapeutic morpholino-substituted compounds
Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
Owner:ASTRAZENECA AB
Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
InactiveUS20050282781A1Affect rate of absorptionOptimal moisture rangeBiocideNervous disorderMetaboliteBenzopyrone
An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested / shown that C20:5n-3 (and C22:6 n-3) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.
Owner:NATREON INC
Benzopyranone compounds, compositions thereof, and methods of treatment therewith
Benzopyranone compounds having the following structure: wherein R1, X, Y and n are as defined here, are disclosed. The compounds of formula (I), wherein R1 is H, can be prepared by demethylation of the corresponding phenolic methyl ether. The compounds are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.
Owner:SIGNAL PHARMA LLC +1
Ratio type fluorescent probe for distinguishing lipid droplets with different polarities as well as preparation method and application thereof
InactiveCN108440475ARealize detectionLow toxicityOrganic chemistryFluorescence/phosphorescenceBenzaldehydeWhole body
The invention provides a ratio type fluorescent probe for distinguishing lipid droplets with different polarities. A chemical name is (E)-7-(N,N-diethylamino)-3-(3-(4-(diphenylamine)phenyl)acrylyl-2H-benzopyrone; N,N-diethylamino salicylic aldehyde reacts with ethyl acetoacetate to generate 3-acetyl-7-(diethylamino)coumarin; the product reacts with 4-(N,N-Diphenylamino)benzaldehyde (4) to obtain the fluorescent probe. The fluorescent probe has a two-photon property and an aggregation-induced light-emitting property; a whole body of the probe is electrically neutral and can be positioned in thelipid droplets with the different polarities very well. The probe has low toxicity, good optical stability and specific response on the polarities; detection on the polarities of the lipid droletps in organs and living bodies is realized. The invention further provides a synthesis method of the probe; the synthesis method has the advantages of simple steps, convenient for purification and high yield.
Owner:UNIV OF JINAN
Benzopyrone compounds with pest killing and sterilizing activity and preparation and use
ActiveCN1616448AHigh insecticidal activitySuitable for comprehensive controlBiocideOrganic chemistryBenzopyroneAryl radical
The present invention relates to a new kind of benzopyrone derivatives expressed in generatal expression (I), and the benzopyrone derivatives are used as pesticide and bactericide.
Owner:SHENYANG SINOCHEM AGROCHEMICALS R&D CO LTD
Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
Owner:BIPAR SCI INC
PARP Modulators and Treatment of Cancer
The invention relates to a method of modulating poly(ADP-ribose)polymerase-1 (PARP-1) activity in a mammal comprising administering to a mammal an effective amount of an organic aromatic compound having from 4 to about 35 carbon atoms, wherein said organic aromatic compound is capable of binding the arginine-34 moiety located in Zinc finger-1 of the PARP-1 enzyme and wherein said organic aromatic compound has electron donating capabilities such that it's π-electron system will interact with the positively charged (cationic) guanidinium moiety of the specific arginine-34 residue of the Zinc-1 finger of PARP-1 and does not contain benzamide or lactam substituents.In particular, substituted benzopyrones and substituted indoles and their pharmaceutical compositions containing such compounds that modulate the activity of PARP-1, are described. The invention is also directed to the composition of matter, kits and methods for their therapeutic and / or prophylactic use in treating diseases and disorders described herein, by administering effective amounts of such compounds. Preferably, the compositions and methods provided herein inhibit PARP activity.
Owner:BIPAR SCI INC
Benzopyrone derivative and application thereof
ActiveCN102206214AHigh affinityLow affinityOrganic active ingredientsNervous disorderBenzopyroneNeuropsychiatric disease
The invention belongs to the field of pharmaceutical chemistry and in particular relates to a benzopyrone derivative and application thereof. The benzopyrone derivative has a structure shown in a formula (I). Discovered by the experiment, the compound can be used for preparing drugs for treating neuropsychiatric diseases.
Owner:HUAZHONG UNIV OF SCI & TECH +1
Chiral center nitrogen heterocyclic carbine precursor salt with quadrol skeleton, synthetic method and application
ActiveCN102153557AEfficient manufacturingThe synthesis method is simpleAsymmetric synthesesEthylenediamineBenzopyrone
The invention provides a chiral center nitrogen heterocyclic carbine precursor salt with a quadrol skeleton, a synthetic method and application. The precursor salt has a structural formula shown in the specifications, and can be prepared from cheap and readily-available chiral substituted diamine as an initial raw material by three-step synthesis, well applied to a polarity inversion reaction of catalytic aldehyde compounds, and used for preparing chiral benzopyrone compounds.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith
Benzopyranone compounds having the following structure: wherein R1, X, Y and n are as defined here, are disclosed. The compounds of formula (I), wherein R1 is H, can be prepared by demethylation of the corresponding phenolic methyl ether. The compounds are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.
Owner:MCKIE JEFFREY A +1
Preparation method of agricultural bactericide
InactiveCN104151233AShort reaction pathSimple and safe operationOrganic chemistryMeth-Agricultural science
Owner:ZHEJIANG TIDE CROP TECH
Oxygenated dibenzo-alpha-pyrone chromoproteins
InactiveUS20050245434A1Increasing cognition learningIncrease awarenessCosmetic preparationsHair cosmeticsPersonal careSterol
A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as core structural fragments, and their biological functions. Pharmaceutical, nutritional, skin care and personal care formulations are also described. These findings establish DCPs as the major bioactives of shilajit.
Owner:NATREON INC
Method for synthesizing high-efficiency green agriculture bactericide
Owner:ZHEJIANG TIDE CROP TECH
Application of isopentene group flavonoid compound used as pancreatic lipase inhibitor
InactiveCN101836975AWeight lossOrganic active ingredientsMetabolism disorderKetoneStructural formula
The invention belongs to the technical field of medicaments, and in particular relates to application of isopentene group flavonoid compound used as a pancreatic lipase inhibitor. The flavonoid compound has the following structural formula and has a chemical name of: (E)-2-(2,4-dihydroxy phenyl)-5,7-dihydroxy-3-(3-methyl-2-butenyl)-6-(3-methy-l-butenyl)-4H-chromene-4-ketone, and can be extracted from artocarpus nitidus. Pancreatic lipase activity tests and experiments of weight loss action in animals prove that the compound has obvious pancreatic lipase inhibitory activity and weight loss action, can be taken as the lead compound for developing novel medicaments for preventing or curing obesity and related metabolic diseases, and also can be used for preparing the medicaments for preventing and curing clinically common multiple obesity and the related metabolic disease.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
Colored curable resin composition
Provided is a colored curable resin composition including colorant, resin, polymerized compounds, and polymerized initiator. The colorant includes compounds including 1,2-benzopyrone framework and C.I. pigment yellow 129 expressed in formula (1), formula (1'), formula (2), formula (3), formula (4) or formula (5). [In the formulas, L represents 2-valence hydrocarbyl etc., AA represents aryl group etc., X represents oxygen atoms, sulphur atoms etc., R1-R4 respectively and independently represent hydrogen atoms, 1-valence hydrocarbyl etc., R5-R9 respectively and independently represent hydrogen atoms, halogen atoms, 1-valence hydrocarbyl etc.].
Owner:SUMITOMO CHEM CO LTD
Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
This invention relates to methods for using benzopyranones, or their pharaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis. The benzopyranones have the formula: wherein R1, R2, R3, n and p are as defined herein.
Owner:SIGNAL PHARMA LLC
Benzopyrone-phenyl-oxazolidone compounds as well as preparation methods and applications thereof
The invention discloses benzopyrone-phenyl-oxazolidone compounds with the following structural general formulas shown in the specification. The compounds have better inhibiting and killing effects on various germs, and some of the benzopyrone-phenyl-oxazolidone compounds have higher bacteriostatic activity than positive control penicillihe G, kalamycin and ketoconazole, so that the benzopyrone-phenyl-oxazolidone compounds can be used for preparing anti-infective drugs. The invention also discloses preparation methods of the benzopyrone-phenyl-oxazolidone compounds.
Owner:玉大燕
Stabilized photoactive composition and use thereof
ActiveCN103080203AAvoid encapsulationSolid-state devicesSemiconductor/solid-state device manufacturingBenzopyroneUltraviolet
Stabilized photoactive composition comprising: - at least one photoactive organic polymer; - at least one light stabilizer selected from hindered amines; - at least one UV absorber selected from triazines, benzoxazinones, benzotriazoles, benzophenones, benzoates, formamidines, cinnamates or propenoates, aromatic propanediones, benzoimidazoles, cycloaliphatic ketones, formanilides including oxamides, cyanoacrylates, benzopyranones, salicylates, or mixtures thereof. Said photoactive composition can be advantageously used in the construction of photovoltaic devices such as, for example, photovoltaic cells, photovoltaic modules, solar cells, solar modules, on both rigid and flexible supports.
Owner:ENI SPA
Novel application of sulfonic benzo-gamma-pyrone compound
The invention relates to novel application of a sulfonic benzo-gamma-pyrone compound, in particular to the application of the sulfonic benzo-gamma-pyrone compound represented by a general formula (I) to HIV virus inhibition, wherein the substituents R1, R2, R3, R4, R5 and R6 of the general formula(I) are defined in the description.
Owner:李泽琳 +1
Benzopyran-4-ketone organic electroluminescence material, as well as preparation method and application of material
InactiveCN106749200AImprove applicabilityImprove current efficiencyOrganic chemistrySolid-state devicesBenzopyranQuantum efficiency
The invention discloses a benzopyran-4-ketone organic electroluminescence material, as well as a preparation method and application of the material. A structural formula of the organic electroluminescence material is as shown in description. The benzopyran-4-ketone organic electroluminescence material provided by the invention is applied to an OLED luminescent device, so that the current efficiency, power efficiency and outer quantum efficiency of the device are greatly improved. The benzopyran-4-ketone organic electroluminescence material provided by the invention has a good application effect and good industrialized prospect.
Owner:VALIANT CO LTD
External preparation for skin
InactiveUS20070105947A1Inhibiting excessive melanin productionKeeping natural-looking whitenessCosmetic preparationsBiocideCentaureidinBenzopyrone
The present invention relates to an external preparation for skin comprising a compound, such as centaureidin(5,7-dihydroxy-3,6-dimethoxy-2-(5-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one); 5,7-dihydroxy-3,6,8-trimethoxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 3,5-diethoxy-6,7-dimethoxy-2-(5-ethoxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; and 5,6-dihydroxy-3,7-dimethoxy-2-(5-hydroxy-2,4-dimethoxyphenyl)-4H-1-benzopyran-4-one; and / or salt thereof and 4-n-butyl resorcinol and / or a salt thereof. The present invention provides an external preparation for skin having a function as a substantial lightening cosmetic that exerts whitening action of inhibiting excessive melanin production and keeping natural-looking whiteness.
Owner:KURARAY CO LTD +1
Compounds used for treating cancer and the use thereof
The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516. The invention also provides new uses of these compounds, compounds such as for the preparation of the treatment of cancer, inhibit cancer cell, cancer stem cell growth and provides a new pharmaceutical composition for treating cancers
Owner:NAT DEFENSE MEDICAL CENT
Use of trisubstituted benzopyranones
The invention relates to the use of trisubstituted benzopyranones in the treatment or prophylaxis of pathological conditions that are related to oxidative stress and / or inflammatory reactions, to novel trisubstituted benzopyranones and to the physiologically acceptable salts thereof. The invention also relates to plant extracts, drugs, dietetic food and pharmaceutical preparations containing said compounds.
Owner:DR VILMAR SHVABE GMBKH EHND KO KG
Benzopyranone compounds, compositions thereof, and methods of treatment therewith
Benzopyranone Compounds having the following structure:wherein R1, R2, X, Y and n are as defined herein, are disclosed. The Benzopyranone Compounds are useful for treating or preventing a bone-resorbing disease, a neoplastic disease, arthritis, a disease exacerbated by the presence of estrogen or a disease improved by the presence of estrogen, comprising administering an effective amount of a Benzopyranone Compound to a patient in need of the treating or preventing; activating the function of estrogen receptor (“ER”) in a bone cell; inhibiting the function of ER in a cancer cell; inhibiting the expression of interleukin-6 (“IL-6”) in a cell; and inhibiting the growth of a neoplastic cell, comprising contacting the cell with an effective amount of a Benzopyranone Compound.
Owner:SIGNAL PHARMA LLC
Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
Owner:BIPAR SCI INC
Benzopyrone derivative, preparation method and medical use thereof
InactiveCN101239959AChange structureHigh affinityOrganic active ingredientsOrganic chemistryArterial smooth muscle cellsBenzopyrone
The invention relates to medicinal chemistry and organic chemistry fields, particularly to benzopyrone derivatives (I). The compounds are useful in treating various medicinal indication related to post-menopause syndrome, uterus fibre lesion and vascular smooth muscle cell proliferation, especially in treating ER-(+) type breast cancer. The invention also discloses a preparing method of the compounds.
Owner:CHINA PHARM UNIV
Synthesis method of benzopyrone and imidazopyridine compound
The invention discloses a synthesis method of a benzopyrone and imidazopyridine compound. The benzopyrone and imidazopyridine compound is directly obtained through the one-pot serial-connection reaction under transient metal catalysis, the benzopyrone structure is established in the one-pot reaction, structure units of benzopyrone and imidazopyridine are subjected to ring fusion, reaction efficiency is high, the resource waste and environment pollution caused by the application of various reagents in the multi-step reaction, the purification of reaction intermediates in multiple steps and the like are avoided, raw materials are easy to prepare, reaction operation is easy and convenient, and the application range of substrates is wide.
Owner:HENAN NORMAL UNIV
PET (Polyethylene terephthalate) base material used for filter membrane, preparation method as well as filter membrane and display screen comprising PET base material
InactiveCN102558792AGood colorImprove near-infraredAlternating current plasma display panelsCold-cathode tubesPolyethylene terephthalate glycolFluorescence
The invention discloses a PET (polyethylene terephthalate) base material used for a filter membrane, a preparation method as well as the filter membrane and a plasma display screen comprising the PET base material. The PET base material comprises one or more of inorganic pigment, organic pigment and dye, wherein the inorganic pigment is one or more of metallic oxide, sulfide, sulfate, chromate and carbon black; the organic pigment is one or more of azo pigment, phthalocyanine pigment, heterocyclic pigment, lake pigment and fluorescent pigment; and the dye is one or more of pyrazolone derivative, quinophthalone, fluorescent polycyclic ring dye, naphthazarin, benzopyrone, azo, fluorescent reactive dye, anthraquinone reactive dye, picene ketone dye, anthraquinone reactive derivative, fluorescent polycyclic ring and polymethylene dye. A material with a toning function is added into the PET base material, thus the phenomenon that chemical substances in pressure-sensitive adhesive (PSA) react with the material with the toning function to generate the discoloration is avoided, and meanwhile, the plasma screen capable of improving color is obtained.
Owner:SICHUAN COC DISPLAY DEVICES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com